Clinical Trials | June 09, 2026
AbbVie showcases broad blood cancer pipeline at EHA 2026 with 21 presentations
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The company will present 21 oral and poster presentations spanning investigational and approved therapies
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
Investigational once-weekly GLP-1 and amylin receptor agonist achieves up to 14.6% weight loss and significant blood sugar reductions
Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial
The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
DST-backed researchers from Pune demonstrate targeted gene-silencing approach that significantly inhibits tumor growth with minimal toxicity
Highlights potential for at-home heart attack risk assessment, offering a new approach to reducing treatment delays
A total of 300 transgender individuals were screened as part of the study, with 82 identified as high-risk due to symptoms of anxiety, depression, and self-harm or suicidal tendencies
Specialised clinic to offer regular device monitoring, battery assessment, rhythm evaluation, and expert cardiac electrophysiology consultation
New PARTNER trial sub-study data show that post-operative ctDNA detection using tumour-informed MRD assays can accurately predict distant recurrence risk in triple-negative breast cancer patients
Subscribe To Our Newsletter & Stay Updated
